Lexeo Therapeutics Investor Relations Material
Latest events
Study Result
Lexeo Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lexeo Therapeutics Inc
Access all reports
Lexeo Therapeutics Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company is advancing a portfolio of gene therapy candidates, including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. Additionally, Lexeo Therapeutics is developing therapies for APOE4 homozygous conditions and CLN2 Batten disease, among others, utilizing its AAVrh10-based gene therapy platform. The company is headquartered in New York, New York, and its shares are listed on the Nasdaq.
Key slides for Lexeo Therapeutics Inc
Corporate Presentation
Lexeo Therapeutics Inc
Corporate Presentation
Lexeo Therapeutics Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
LXEO
Country
🇺🇸 United States